Dual optic accommodating IOL offers good quality of life

Article

Dual optic accommodating IOLs provide a more noticeable positive impact on a patient's quality of life than multifocal IOLs, according to Andrea Galvis and Ivan Ossma of the Instituto para Ninos Ciegos y Sordos, Columbia.

Dual optic accommodating IOLs provide a more noticeable positive impact on a patient's quality of life than multifocal IOLs, according to Andrea Galvis and Ivan Ossma of the Instituto para Ninos Ciegos y Sordos, Columbia.

They conducted a non-concurrent case series involving four patient groups implanted with multifocal IOLs or dual optic accommodating lenses: Alcon's Acrysof ReSTOR (n=27), AMO's ReZoom (n=28), AMO's Tecnis multifocal (n=34) and Visiogen's Synchrony dual optic accommodating IOL (n=31).

Subjects were matched based on age at time of implant and the absence of ocular co-morbidity. An adapted VF-7 questionnaire was completed by subjects three and six months after the second eye had received the implant and a questionnaire regarding halo and glare sensitivity was also mailed to all subjects.

The preoperative VF-7 scores ranged from 33.4 to 37.5 for all four groups. At six months follow-up, the mean VF-7 scores were 78.4 in the ReSTOR group, 81.7 in the Tecnis group, 71.5 in the ReZoom group and 84.2 in the Synchrony group. Halos occurred most often in the ReZoom group (21%) and least often in the Synchrony group (6.4%).

Glavis and Ossma concluded from their study that the dual optic accommodating IOL, Synchrony, not only offers patients a better quality of life, but it also yields a greater range of vision when compared to multifocal lenses.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.